Invesco Ltd. Boosts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Invesco Ltd. increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 17.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,034,180 shares of the medical research company's stock after purchasing an additional 151,159 shares during the quarter. Invesco Ltd. owned 2.02% of Charles River Laboratories International worth $190,910,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of CRL. Fiduciary Financial Group LLC raised its holdings in shares of Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after purchasing an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. boosted its stake in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares in the last quarter. M&T Bank Corp grew its position in shares of Charles River Laboratories International by 3.4% during the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after acquiring an additional 66 shares during the period. Cornerstone Investment Partners LLC raised its holdings in Charles River Laboratories International by 3.7% in the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock worth $358,000 after purchasing an additional 69 shares during the period. Finally, Metis Global Partners LLC grew its holdings in Charles River Laboratories International by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock valued at $318,000 after purchasing an additional 72 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Charles River Laboratories International Trading Down 0.5 %

Shares of NYSE:CRL traded down $0.58 during mid-day trading on Tuesday, reaching $106.02. 2,845,054 shares of the company were exchanged, compared to its average volume of 878,893. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The firm's 50-day simple moving average is $155.52 and its 200 day simple moving average is $176.21. The firm has a market cap of $5.21 billion, a price-to-earnings ratio of 706.79, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International's revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.46 EPS. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Mizuho reduced their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. Morgan Stanley lowered their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Barclays dropped their target price on shares of Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Finally, UBS Group restated a "neutral" rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and an average target price of $182.00.

Insiders Place Their Bets

In related news, COO Birgit Girshick purchased 1,514 shares of the business's stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO James C. Foster acquired 6,075 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).